Clinical Trial

A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 14, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Given that a significant proportion of locally advanced gastric cancer patients still die from tumor recurrence after surgery, with long-term therapeutic outcomes stagnating and difficult to further improve, especially for patients with poor tumor regression grade (TRG) after surgery, this study aims to explore a new model of adjuvant therapy by conducting research on the use of Fruquintinib in combination with standard chemotherapy for postoperative treatment of HER2-negative gastric cancer patients with poor TRG, in order to bring greater survival benefits to patients.
Trial Details
NCT Number NCT06774222
Lead Sponsor Henan Cancer Hospital
Conditions Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment 69 participants
Start Date 2023-09-12
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-14